Phase 2 Study Evaluates Response-Based Adaptive Radiotherapy for NSCLC | Docwire News
Personalized response-based adaptive radiation therapy (RT) with concurrent chemotherapy provided excellent tumor control while minimizing rates of high-grade toxicities in NSCLC.